Intraoperative Bone Marrow Aspirate Concentrate Injections: Evaluating Outcomes in a Randomized Controlled Trial

Launched by AMERICAN HIP INSTITUTE · Dec 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment option for patients with labral tears and femoroacetabular impingement in the hip. The researchers want to find out if using a special injection called bone marrow aspirate concentrate (BMAC) during hip surgery can improve results compared to surgery alone. BMAC is made by taking a small sample of bone marrow from your hip, which is done while you are under anesthesia. This injection is FDA-approved and has been researched before. The goal is to see if adding BMAC to surgery helps patients recover better or have less pain.

To participate in the study, you need to be an adult who is scheduled for hip arthroscopy surgery to treat specific hip problems. You should have symptoms like pain in the front of your hip or groin and limited movement, along with imaging tests showing certain issues in the hip joint. However, if you have had previous hip surgery, have certain types of arthritis, or other specific conditions, you may not be eligible. If you join the trial, you will be randomly assigned to receive either the BMAC injection along with your surgery or just the surgery itself. This study is not yet recruiting participants, but it aims to provide insights into the effectiveness of this treatment approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing primary hip arthroscopy to treat femoroacetabular impingement
• • Subjects will require a clinical diagnosis of intra-articular pathology consisting of anterior hip and/or groin pain with restricted hip motion and positive impingement testing.
• • Study inclusion also requires the radiographic hallmarks of Cam type femoroacetabular impingement with an alpha angle greater than 60 degrees on Dunn lateral views and advanced imaging with magnetic resonance imaging (MRI) or magnetic resonance arthrography (MRA) confirming chondrolabral pathology.
• Exclusion Criteria:
• • Patients who have had prior hip arthroscopy or hip surgery, Tonnis grade II or higher radiographic osteoarthritis, congenital hip deformities including Legg-Calve-Perthes or Slipped Capital Femoral Epiphysis, rheumatologic conditions, or workers compensation claims.
• • Patients undergoing additional arthroscopic procedures such as trochanteric bursectomy or gluteus medius repair will also be excluded.